MOTS-c vs SLU-PP-332: what the research actually says

Last updated 2026-07-24

What are MOTS-c and SLU-PP-332, and why are people comparing them?

Both get marketed as "exercise in a pill," which is why they end up in the same conversation. That framing is a sales pitch, not a finding, and it's worth separating from what the actual papers show. MOTS-c is a 16-amino-acid peptide encoded in a short open reading frame inside the mitochondrial 12S rRNA gene, not the nuclear genome. It's naturally produced in humans and other mammals. Under metabolic stress, MOTS-c translocates to the nucleus and regulates gene expression there, acting as a communication link between mitochondria and the nuclear genome ^[1]. A 2023 Frontiers in Endocrinology review calls it "a promising mitochondrial-derived peptide for therapeutic exploitation," language that signals early-stage interest rather than proven therapy ^[2]. SLU-PP-332 is a fully synthetic small molecule, not a peptide, developed by medicinal chemists at Saint Louis University as a pan-agonist of the estrogen-related receptors (ERRalpha, beta, gamma). It doesn't occur naturally in the body. It's a research tool compound designed to switch on ERR-driven mitochondrial biogenesis and oxidative metabolism pathways, the same pathways exercise activates. The original published work is in mice; there is no PubMed-indexed human trial for SLU-PP-332 as of this writing. That asymmetry, one is an endogenous peptide with a growing mechanistic literature, the other is a synthetic molecule with a much thinner and younger published record, is the single most important fact in this comparison.

How is MOTS-c actually studied in humans and animals?

MOTS-c research spans two tracks: metabolic regulation and a long tail of organ-specific and disease-specific mechanistic work. None of it is a completed human clinical trial with hard clinical endpoints like HbA1c reduction or VO2 max change in a registered trial. The foundational paper, published in Cell Metabolism in 2015, found that MOTS-c administration promoted metabolic homeostasis and reduced obesity and insulin resistance in mouse models ^[3]. A follow-up Cell Metabolism paper in 2018 established the nuclear translocation mechanism under metabolic stress, showing MOTS-c isn't just a mitochondrial signal, it directly regulates nuclear gene transcription ^[1]. A 2019 BioEssays review frames MOTS-c as a mitochondrial-encoded regulator of the nucleus, consolidating that mechanistic picture ^[4]. Beyond metabolism, the published record includes: skeletal muscle differentiation in vitro ^[5], reduced myostatin and atrophy signaling in a rodent model ^[6], protection against immobilization-induced muscle atrophy via reduced lipid infiltration ^[7], bone metabolism regulation ^[8], cartilage protection in an osteoarthritis model via Nrf2 ^[9], antiviral activity against hepatitis B in liver cells ^[10], lung ischemia-reperfusion protection ^[11], acute lung injury and ferroptosis suppression ^[12], pulmonary fibrosis attenuation ^[13], allergic asthma airway protection ^[14], gestational diabetes glucose control in a rodent/cell model ^[15], pancreatic islet cell senescence prevention ^[16], diabetic liver fibrosis reduction that the authors describe as mimicking exercise at the molecular level ^[17], and even ovarian cancer suppression via a ubiquitination pathway ^[18]. A 2023 Metabolites paper summarizes much of this as "MOTS-c Functionally Prevents Metabolic Disorders," again based on preclinical models ^[19]. That's a genuinely wide biology footprint. It's also, almost without exception, mouse, rat, or cultured cell data. Read mots-c for the full breakdown of what's mechanistic versus what's closer to translational.

Does MOTS-c actually mimic exercise, or is that just marketing?

"Exercise mimetic" is doing a lot of work in MOTS-c marketing, and the underlying research is more specific than the slogan. MOTS-c blood levels rise with acute exercise in some human and rodent studies, and the compound is part of what researchers call mitohormesis, the idea that mild mitochondrial stress (like exercise) triggers adaptive signaling that improves metabolic resilience. A 2022 review in Diabetes & Metabolism Journal, titled "Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c)," lays out this connection as a proposed mechanism, not a demonstrated clinical equivalence ^[20]. A 2021 review in Biochimica et Biophysica Acta specifically on mitochondrial-derived peptides and exercise makes the same point: MOTS-c is exercise-responsive, which is different from being exercise-replacing ^[21]. The 2025 diabetic liver fibrosis paper explicitly frames MOTS-c as mimicking exercise-associated molecular signaling (Keap1-Nrf2-Smad2/3) in a rodent model of disease ^[17]. That's a legitimate, specific, citable finding. It is not evidence that injecting MOTS-c gives a sedentary human the cardiovascular, muscular, and metabolic adaptations of actual training. Nobody has run that trial. Until someone does, "exercise in a pill" is a hypothesis riding on rodent mechanism papers, not a conclusion.

What does the research on SLU-PP-332 actually show?

Far less than MOTS-c's literature, and none of it in humans. SLU-PP-332 is newer to the research chemical market than MOTS-c, and the compound class it belongs to, ERR pan-agonists, is itself still an emerging area of exercise-mimetic pharmacology. The mechanistic pitch is that ERRalpha, beta, and gamma are nuclear receptors that coordinate mitochondrial biogenesis, oxidative fiber type shifting, and fatty acid oxidation, largely overlapping with pathways activated by endurance training and by PGC-1alpha signaling. Turning them on with a synthetic agonist is meant to trigger some of that adaptation without the training stimulus. That's a coherent pharmacological hypothesis. It is not the same as clinical proof. The research pack behind this article, built from the current published MOTS-c literature, contains zero SLU-PP-332 citations, because there is no comparable published human or even extensive animal safety record to cite alongside it. That absence is itself the finding: if you're choosing between the two based on depth of published evidence, MOTS-c has a decade-plus, multi-organ-system literature (even if entirely preclinical); SLU-PP-332 has a much newer and thinner one. Treat any specific numeric claims about SLU-PP-332 dosing or effect size that you see in forums or vendor pages with real skepticism until they're tied to a named, checkable paper.

MOTS-c vs SLU-PP-332: side by side

The table understates one thing: MOTS-c's literature is more than older, it's broader across disease models, which matters if you're trying to gauge how seriously the peptide biology field is taking the molecule versus how much of the interest is coming from supplement marketing.

Are either of these legal to buy or use in the US?

Neither is FDA-approved as a drug for any human indication. You will not find MOTS-c or SLU-PP-332 in the Drugs@FDA database of approved products [Drugs@FDA]. That means anything sold as either compound is being marketed outside the normal drug approval pathway, typically labeled "research use only." For compounding pharmacies, the relevant legal test is narrower than most sellers imply. Under 21 U.S.C. 353a, a compounded human drug generally must use a bulk substance that appears on FDA's 503A Bulks List (21 CFR 216.23) or, for outsourcing facilities, the 503B Bulks List (21 CFR 216.24) [21 U.S.C. 353a][21 CFR 216.23][21 CFR 216.24]. FDA maintains and updates the current list of bulk drug substances nominated for compounding use, and it explains the standard on its bulk drug substances page: substances must be evaluated for physical and chemical characterization, and for safety and effectiveness data, before they can be used in compounded drugs [FDA Bulk Drug Substances]. Neither MOTS-c nor SLU-PP-332 currently sits on an FDA-final Bulks List for general human use, so any compounded product claiming to legally contain either one deserves real scrutiny about its sourcing chain. Selling either compound with disease-treatment claims also triggers FDA's "intended use" doctrine. Under 21 CFR 201.128, a product's intended use is established by labeling claims, advertising, and how the seller represents it, not by a disclaimer alone [21 CFR 201.128]. A vial labeled "research use only" that's marketed with claims about fat loss, insulin sensitivity, or muscle preservation is legally walking a line the FDA has pursued in other peptide categories. If you're going to use either compound, understand you're operating in a regulatory gray zone, not a cleared drug market.

What are the safety data for MOTS-c versus SLU-PP-332?

Thin for both, but not equally thin. MOTS-c has more published toxicology-adjacent signal simply because it's been studied longer and across more disease models, even though almost none of that is formal human safety trial data. A 2026 Sports Medicine paper specifically reviewing "Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance" places MOTS-c in the unapproved category and flags the general problem across this peptide class: efficacy claims routinely outpace controlled human safety data ^[22]. That's a useful outside check on the marketing. One genuinely cautionary data point comes from a 2018 Rejuvenation Research paper titled "Mitochondrial-Derived Peptides Exacerbate Senescence" ^[23]. This finding matters because it complicates the simple "MOTS-c is protective" narrative; the mitochondrial-derived peptide family's effects appear context-dependent, and readers should not assume uniform benefit across all MDPs or all tissue states. This is exactly the kind of nuance that gets stripped out of marketing copy. For SLU-PP-332, there is no comparable published safety literature to point to at all in the sources reviewed here, which isn't reassurance, it's an information gap. Absence of reported harm in a compound with almost no published exposure data is not the same as a clean safety record. For a fuller rundown of documented and theoretical MOTS-c risks, see mots-c side effects.

Which one has better evidence for fat loss and insulin sensitivity?

MOTS-c, by a clear margin, though "clear margin" still means rodent and cell data, not human clinical trial results. The 2015 Cell Metabolism paper is the foundational reference: MOTS-c reduced obesity and insulin resistance and promoted metabolic homeostasis in mouse models ^[3]. A 2022 Pharmacological Research paper extended this to a gestational diabetes model, showing MOTS-c relieved hyperglycemia and insulin resistance ^[15]. A 2025 Experimental & Molecular Medicine paper found MOTS-c prevents pancreatic islet cell senescence in a model relevant to diabetes progression ^[16]. A 2023 Diabetes & Metabolism Journal review connects MOTS-c specifically to diabetes and aging-related disease mechanisms ^[24], and a 2025 Cardiovascular Drugs and Therapy paper even asks, somewhat provocatively in its title, whether MOTS-c is a "Magical Molecule for Diabetic Cardiomyopathy" ^[25], which should read as a hypothesis-generating review title, not a settled answer. SLU-PP-332's metabolic evidence, in the sources checked for this article, doesn't have a comparable stack of disease-model papers to cite. That doesn't mean the compound doesn't work through its proposed ERR mechanism; it means the published record hasn't caught up to the marketing claims yet, and readers should weight that gap heavily when deciding what to believe.

Which one has better evidence for muscle and strength?

MOTS-c again has the deeper published record, spanning differentiation, atrophy prevention, and a specific molecular target in muscle tissue. A 2022 Peptides paper found MOTS-c promotes muscle differentiation in cultured cells ^[5]. A 2024 iScience paper identified a direct mechanism: MOTS-c binds and activates CK2 (casein kinase 2) to modulate skeletal muscle function ^[26], giving researchers an actual molecular target rather than just a downstream effect. A 2021 paper in American Journal of Physiology - Endocrinology and Metabolism found MOTS-c reduces myostatin and muscle atrophy signaling in a rodent model ^[6], directly relevant to anyone interested in muscle preservation during aging or disuse. A 2024 follow-up paper in the same journal found MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration into muscle tissue ^[7], a mechanism distinct from the myostatin pathway and worth noting as a second, independent line of evidence. SLU-PP-332's muscle-related work centers on fiber-type shifting toward more oxidative, endurance-type fibers via ERR activation, again mouse-only in the sources available. If your interest is specifically sarcopenia or disuse atrophy prevention, MOTS-c currently has more named, checkable mechanistic papers behind it. Neither compound has a published human strength or hypertrophy trial.

How do dosing and administration compare?

This is an area where the honest answer is: there's no standardized, clinically validated human dosing protocol for either compound, because neither has completed the human trials that would establish one. Whatever dosing schedules circulate in peptide forums or vendor guides are extrapolated from animal study doses (scaled by body weight, often with real error margins) or copied from other researchers' informal protocols, not derived from dose-ranging human trials. MOTS-c is typically handled as a subcutaneous injection in the protocols people describe, which raises its own reconstitution, storage, and injection-technique questions. If you want the mechanics of that (not a recommendation to use it, but the practical how-to for people who've already decided), see mots-c peptide injection and mots-c dosage. A mots-c 10mg dosage calculator can help with reconstitution math once you have a vial, but math doesn't substitute for missing safety data. SLU-PP-332, being an experimental small molecule rather than a peptide, would in principle allow oral dosing in future drug development, one of its proposed advantages over peptide therapeutics that require injection. But that's a formulation possibility, not a demonstrated human dosing regimen. Nobody should treat any currently circulating SLU-PP-332 dosing number as clinically validated.

If I'm going to try one of these, what should I actually do?

Be honest with yourself about what tier of evidence you're acting on. Both compounds sit in the "promising preclinical biology, no human trial data" tier. That's a real category in drug development, most future medicines start there, but it's a different risk profile than a supplement with even a single completed Phase 2 human trial. If you're going to use either, the sourcing question is at least as important as the compound choice. A product labeled MOTS-c or SLU-PP-332 sold with no certificate of analysis, no third-party purity testing, and no traceable manufacturing chain carries a real risk of being under-dosed, contaminated, or simply mislabeled, independent of whatever the peptide biology itself might do. Read mots-c peptide buy before purchasing anything. For readers who want the provider-reviewed route rather than an anonymous vendor, MOTS-c Co reviews sourcing options and points toward providers that work with named, accountable fulfilling pharmacy partners rather than unverifiable overseas suppliers. That's a sourcing decision, not a medical claim, and it doesn't change the underlying evidence gap described throughout this article.

So which one actually wins, MOTS-c or SLU-PP-332?

On depth of published evidence, MOTS-c wins clearly: over a decade of papers across metabolism, muscle, bone, lung, liver, cardiac, and cancer biology, including the foundational 2015 Cell Metabolism paper ^[3] and the mechanistic 2018 nuclear translocation paper ^[1]. On regulatory status, they're tied: neither is FDA-approved, neither sits on a final Bulks List for compounding, and both live in the same gray-market space. On human clinical evidence, neither wins, because neither has any. That's the sentence worth remembering more than any comparison table: "MOTS-c vs SLU-PP-332" is really a comparison of two preclinical hypotheses with different amounts of published mechanistic support behind them, not a comparison of two proven therapies. If someone tells you one of these compounds is a settled, clinically proven "exercise in a pill," they're selling you marketing, not describing the literature.

Frequently asked questions

Is SLU-PP-332 the same thing as MOTS-c?

No. MOTS-c is a naturally occurring 16-amino-acid peptide encoded in mitochondrial DNA. SLU-PP-332 is a fully synthetic small molecule developed as an ERR receptor pan-agonist. They act through different mechanisms and belong to entirely different chemical classes, though both get marketed with similar exercise-mimetic language.

Which has more human research, MOTS-c or SLU-PP-332?

Neither has published, completed human clinical trials in the sources reviewed here. MOTS-c has a much larger body of published preclinical (mouse, rat, cell culture) research spanning over a decade, starting with a 2015 Cell Metabolism paper [PMID 25738459]. SLU-PP-332's published record is newer and thinner by comparison.

Is MOTS-c FDA-approved?

No. MOTS-c does not appear in the Drugs@FDA database of approved drug products and is not on FDA's current 503A or 503B Bulks List for compounding. Any MOTS-c product is sold outside the standard approved-drug pathway, typically labeled for research use only.

Is SLU-PP-332 legal to buy in the US?

It is not FDA-approved and is not on FDA's Bulks List for compounding. It's generally sold as a research chemical rather than a drug product. That doesn't make possession automatically illegal in every context, but selling it with disease-treatment claims raises the same FDA intended-use concerns that apply to MOTS-c.

Does MOTS-c actually work like exercise?

MOTS-c is exercise-responsive (levels change with physical activity) and shares some mitohormesis signaling pathways with exercise adaptation, per a 2022 Diabetes & Metabolism Journal review [PMID 35656563]. That's different from proof it replicates exercise's effects in humans. No published human trial has tested that claim directly.

What did the original 2015 MOTS-c study find?

The 2015 Cell Metabolism paper found that MOTS-c administration promoted metabolic homeostasis and reduced obesity and insulin resistance in mouse models [PMID 25738459]. It's the foundational metabolic paper in the MOTS-c literature, but it's mouse data, not a human clinical result.

Can MOTS-c or SLU-PP-332 help with muscle atrophy or sarcopenia?

MOTS-c has published rodent evidence for reducing myostatin and atrophy signaling [PMID 33554779] and preventing immobilization-induced muscle atrophy by suppressing lipid infiltration [PMID 38170165]. SLU-PP-332's muscle evidence centers on fiber-type shifting in mice. Neither has a published human muscle outcome trial.

Are there safety concerns specific to MOTS-c?

A 2018 Rejuvenation Research paper found that mitochondrial-derived peptides as a class can exacerbate senescence in certain contexts [PMID 30058454], complicating the simple protective narrative. A 2026 Sports Medicine review also flags MOTS-c as an unapproved peptide lacking controlled human safety data [PMID 41966639].

Why don't compounding pharmacies legally sell MOTS-c or SLU-PP-332?

Under 21 U.S.C. 353a, compounded drugs generally must use bulk substances on FDA's 503A or 503B Bulks List (21 CFR 216.23, 216.24). Neither compound currently sits on a final Bulks List for this use, so legally compounded, FDA-recognized versions aren't broadly available through that pathway.

Does MOTS-c help with diabetes?

Preclinical evidence is genuinely broad here: a 2022 Pharmacological Research paper found MOTS-c relieved hyperglycemia and insulin resistance in a gestational diabetes model [PMID 34798268], and a 2025 paper found it prevents pancreatic islet cell senescence relevant to diabetes progression [PMID 40855115]. All of this is preclinical, not a human diabetes trial.

Is one of these safer than the other?

Neither has completed human safety trials, so "safer" can't be answered directly. MOTS-c has more published preclinical toxicology-adjacent data simply from broader study, including at least one paper flagging context-dependent senescence effects [PMID 30058454]. SLU-PP-332 has less published safety signal in either direction, which is itself a gap, not reassurance.

What is MOTS-c's mechanism of action?

MOTS-c is produced from a short open reading frame in mitochondrial DNA and, under metabolic stress, translocates to the cell nucleus where it directly regulates nuclear gene expression, according to a 2018 Cell Metabolism paper [PMID 29983246]. It also directly binds and activates CK2 in skeletal muscle, per a 2024 iScience paper [PMID 39559755].

Where can I read more about MOTS-c dosing and injection technique?

See our dedicated guides on mots-c dosage and mots-c peptide injection for reconstitution, storage, and administration mechanics. Note that no dosing protocol for MOTS-c is derived from a completed human dose-ranging trial.

Sources

1. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): Review describing MOTS-c as a promising mitochondrial-derived peptide for therapeutic exploitation
2. PubMed, Cell Metabolism 2015 (PMID 25738459): Foundational study finding MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in mouse models
3. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression via USP7-mediated LARS1 deubiquitination attenuation
4. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes mellitus model
5. PubMed, Redox Biology 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation
6. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate nuclear gene expression under metabolic stress
7. PubMed, Metabolites 2023 (PMID 36677050): Review summarizing evidence that MOTS-c functionally prevents metabolic disorders in preclinical models
8. PubMed, Cardiovascular Drugs and Therapy 2025 (PMID 40172798): Review evaluating MOTS-c's potential role in diabetic cardiomyopathy
9. PubMed, iScience 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by directly binding and activating CK2
10. PubMed, BioEssays 2019 (PMID 31378979): Review consolidating MOTS-c's mechanistic role as a mitochondrial-encoded regulator of the nucleus
11. PubMed, Sports Medicine 2026 (PMID 41966639): Review of safety and efficacy of approved and unapproved peptide therapies including MOTS-c for athletic performance
12. PubMed, Peptides 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
13. PubMed, American Journal of Physiology-Endocrinology and Metabolism 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
14. PubMed, Frontiers in Physiology 2023 (PMID 37200834): Review of MOTS-c's role in regulation of bone metabolism
15. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction and cartilage degradation in osteoarthritis via Nrf2
16. PubMed, Gut 2024 (PMID 37788894): MOTS-c mitochondrial remodeling contributes to antiviral activity during hepatitis B infection
17. PubMed, European Journal of Pharmacology 2023 (PMID 37290680): MOTS-c suppresses ferroptosis and alleviates acute lung injury via PPARgamma signaling
18. PubMed, Mitochondrion 2023 (PMID 37307934): MOTS-c identified as a potential anti-pulmonary fibrosis factor derived from mitochondria
19. PubMed, International Immunopharmacology 2025 (PMID 40472776): MOTS-c attenuates airway barrier dysfunction in allergic asthma via Nrf2 pathway
20. PubMed, Diabetes & Metabolism Journal 2023 (PMID 36824008): Review connecting MOTS-c to diabetes and aging-related disease mechanisms
21. PubMed, Experimental & Molecular Medicine 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes onset
22. PubMed, American Journal of Physiology-Endocrinology and Metabolism 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling in a rodent model
23. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): Review of mitochondrial-derived peptides including MOTS-c in relation to exercise responsiveness
24. PubMed, Rejuvenation Research 2018 (PMID 30058454): Study finding mitochondrial-derived peptides can exacerbate senescence in certain contexts
25. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): Review connecting exercise, mitohormesis, and MOTS-c signaling mechanisms
26. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimics exercise-associated molecular signaling to combat diabetic liver fibrosis in a rodent model
27. 21 U.S.C. 353a, pharmacy compounding: Legal standard requiring bulk drug substances used in compounding to meet FDA criteria
28. eCFR, 21 CFR 216.23, 503A Bulks List: Regulation establishing the 503A bulk drug substances list for compounding
29. eCFR, 21 CFR 216.24, 503B Bulks List: Regulation establishing the 503B bulk drug substances list for outsourcing facilities
30. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA explains criteria substances must meet, including safety and effectiveness data, before compounding use
31. eCFR, 21 CFR 201.128, meaning of intended uses: Regulation defining how labeling and marketing claims establish a product's intended use
32. FDA, Drugs@FDA database: Database confirming neither MOTS-c nor SLU-PP-332 is an FDA-approved drug product